$2.29
6.15%
Nasdaq, Nov 10, 03:59 pm EST. Closed.
ISIN
CH0329023102
Symbol
ACIU

AC Immune SA Stock price

$2.29
-0.16 6.53% 1M
-0.54 19.08% 6M
-0.85 27.07% YTD
-1.06 31.64% 1Y
-0.61 21.03% 3Y
-3.82 62.52% 5Y
-11.86 83.82% 10Y
-13.37 85.38% 20Y
Nasdaq, Closing price Tue, Nov 10 2026
-0.15 6.15%
ISIN
CH0329023102
Symbol
ACIU
Industry

Is AC Immune SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,093 stocks worldwide.

Key metrics

Basic
Market capitalization
$233.1m
Enterprise Value
$146.7m
Net debt
positive
Cash
$91.3m
Shares outstanding
101.8m
Valuation
P/E
negative
P/S | estimate
11.0 | 9.1
EV/Sales | estimate
6.9 | 5.7
EV/FCF | ex SBC
negative | -
P/B
5.5
Financial Health
Equity Ratio
29.1%
Return on Equity
-157.0%
ROCE
-88.0%
ROIC
-
Debt/Equity
0.1
Financials
Revenue | estimate
$21.2m | $25.7m
EBITDA
$-50.8m
EBIT
$-53.5m
Net Income
$-52.3m
Free Cash Flow | ex SBC
$-61.9m | -
Growth
Revenue | estimate
-39.5% | 492.9%
EBITDA
12.4%
EBIT
11.9%
Net Income
14.6%
Free Cash Flow
-17.1%
Margin
Gross
-
EBITDA
-239.2%
EBIT
-252.2%
Net
-246.5%
Free Cash Flow | ex SBC
-291.8% | -
More
EPS
$-0.5
FCF per Share
$-0.6
Short interest
7.0%
Employees
106
Rev per Employee
$40.0k

AC Immune SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a AC Immune SA forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a AC Immune SA forecast:

Buy
90%
Hold
10%

AC Immune SA Events

Past Events
NOV
4
Q3 2026 Earnings Call
7 days ago

Financial data from AC Immune SA

Jun '26
+/-
%
21 21
39% 39%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
17% 17%
76%
- Research and Development Expense 56 56
27% 27%
262%
-51 -51
12% 12%
-239%
- Depreciation and Amortization 2.76 2.76
1% 1%
13%
EBIT (Operating Income) EBIT -54 -54
12% 12%
-252%
Net Profit -52 -52
15% 15%
-247%

In millions USD.

Don't miss a Thing! We will send you all news about AC Immune SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AC Immune SA Stock News

Neutral
GlobeNewsWire
●
7 days ago
AC Immune announces financial and corporate updates for the quarter ended September 30, 2026, with positive progress across its wholly-owned pipeline.
Neutral
GlobeNewsWire
●
about 2 months ago
All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizations Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement Discussions with FDA regarding future development path planned for early 2027 AC Immune to host webcast & conf...
Neutral
GlobeNewsWire
●
3 months ago
AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting inflammation.
More AC Immune SA News

Company Profile

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Head office Switzerland
CEO Prof. Pfeifer
Employees 106
Founded 2003
Website www.acimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today